Guidelines for the preventive treatment of ischaemic stroke and TIA (I). Update on risk factors and life style;Guía para el tratamiento preventivo del ictus isquémico y AIT (I). Actuación sobre los factores de riesgo y estilo de vida

Neurologia

Volumn 27, Issue 9, 2012, Pages 560-574

  Fuentes, B ^a   Gallego J ^a   Gil Nunez A ^a   Morales, A ^a   Purroy, F ^a   Roquer, J ^a   Segura, T ^a   Tejada, J ^a   Lago, A ^a   Diez Tejedor E ^a   Alonso de Lecinana M ^a   Alvarez Sabin J ^a   Arenillas, J ^a   Calleja, S ^a   Casado, I ^a   Castellanos, M ^a   Castillo, J ^a   Davalos A ^a   Diaz Otero F ^a   Egido, J A ^a   Lopez Fernandez J C ^a   Freijo, M ^a   Garcia Pastor A ^a   Gilo, F ^a   Irimia, P ^a   Maestre, J ^a   Masjuan, J ^a   Marti Fabregas J ^a   Martinez Sanchez P ^a   Martinez Vila E ^a   Molina, C ^a   Nombela, F ^a   Ribo M ^a   Rodriguez Yanez M ^a   Rubio, F ^a   Serena, J ^a   Simal, P ^a   Vivancos, J ^a   more..

^a NONE

Author keywords

Guidelines; Ischaemic stroke; Prevention; Transient ischemic attack

Indexed keywords

CONTRACEPTIVE AGENT; LIPID;

ALCOHOL CONSUMPTION; BLOOD PRESSURE; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; DIABETES MELLITUS; DIET; EMBOLISM; HORMONE SUBSTITUTION; HUMAN; HYPERHOMOCYSTEINEMIA; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; RISK FACTOR; SHORT SURVEY; SLEEP DISORDERED BREATHING; SMOKING; TRANSIENT ISCHEMIC ATTACK;

BRAIN ISCHEMIA; EVIDENCE-BASED MEDICINE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; LIFE STYLE; RISK FACTORS; SPAIN; STROKE;

EID: 84868612460     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2011.06.002     Document Type: Short Survey

References (195)

1. Instituto Nacional de Estadística. Defunciones según causa de muerte 2006. [consultado 29 Jul 2011]. Disponible en: http://www.ine.es/prensa/np490.pdf.
2. Adams R.J., Chimowitz M.I., Alpert J.S., Awad I.A., Cerqueria M.D., Fayad P., et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Stroke 2003, 34:2310-2322.
3. Centre for Evidence Based Medicine. [consultado 29 Jul 2011]. Disponible en: http://www.cebm.net/.
4. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
5. Lawes C.M., Bennett D.A., Feigin V.L., Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke 2004, 35:776-785.
6. Kjeldsen S.E., Julius S., Hedner T., Hansson L. Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press 2001, 10:190-192.
7. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
8. Lawes C.M., Vander Hoorn S., Law M.R., Elliott P., MacMahon S., Rodgers A. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J Hypertens 2006, 24:423-430.
9. Ebrahim S., Beswick A., Burke M., Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev 2006, 4:CD001561.
10. Rashid P., Leonardi-Bee J., Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003, 34:2741-2748.
11. Zhang H., Thijs L., Staessen J.A. Blood pressure lowering for primary and secondary prevention of stroke. Hypertension 2006, 48:187-195.
12. Fuentes B., Ortega-Casarrubios M.A., Martinez P., Diez-Tejedor E. Action on vascular risk factors: importance of blood pressure and lipid lowering in stroke secondary prevention. Cerebrovasc Dis 2007, 24(Suppl 1):96-106.
13. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 1993, 24:543-548. The Dutch TIA Trial Study Group.
14. Eriksson S., Olofsson B., Wester P.O. Atenolol in secondary prevention after stroke. Cerebrovasc Dis 1995, 5:21-25.
15. Wiysonge C.S., Bradley H., Maysi B.M., Maroney R., Mbewu A., Opie L.H., et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007, 1:CD002003.
16. Hypertension-Stroke Cooperative Group Effect of antihypertensive treatment on stroke recurrence. JAMA 1974, 229:409-418.
17. PATS Collaborating Group Post-stroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. Chin Med J (Engl) 1995, 108:710-717.
18. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
19. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033-1041.
20. Schrader J., Luders S., Kulschewski A., Hammersen F., Plate K., Berger J., et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005, 36:1218-1226.
21. Yusuf S., Diener H.C., Sacco R.L., Cotton D., Ounpuu S., Lawton W.A., et al. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. N Engl J Med 2008, 359:1225-1237.
22. Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559. ONTARGET Investigators.
23. Turnbull F., Neal B., Algert C., Chalmers J., Chapman N., Cutler J., et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005, 165:1410-1419.
24. Gil-Nunez A.C., Vivancos-Mora J. Blood pressure as a risk factor for stroke and the impact of antihypertensive treatment. Cerebrovasc Dis 2005, 20(Suppl 2):40-52.
25. Fuentes B., Fernandez-Dominguez J., Ortega-Casarrubios M.A., SanJose B., Martinez-Sanchez P., Diez-Tejedor E. Treatment with angiotensin receptor blockers before stroke could exert a favourable effect in acute cerebral infarction. J Hypertens 2010, 28:575-581.
26. JAMA 2001, 285:2486-2497. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults AT Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
27. Almdal T., Scharling H., Jensen J.S., Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004, 164:1422-1426.
28. Hillen T., Coshall C., Tilling K., Rudd A.G., McGovern R., Wolfe C.D., et al. Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke 2003, 34:1457-1463.
29. Mancia G. Optimal control of blood pressure in patients with diabetes reduces the incidence of macro and microvascular events. J Hypertens Suppl 2007, 25:S7-S12.
30. Kearney P.M., Blackwell L., Collins R., Keech A., Simes J. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125. Cholesterol Treatment Trialists' (CTT) Collaborators,.
31. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T. N Engl J Med 2008, 358:2545-2559. Action to Control Cardiovascular Risk in Diabetes Study Gr*oup. AT Effects of intensive glucose lowering in type 2 diabetes.
32. Patel A., MacMahon S., Chalmers J., Neal B., Billot L. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. ADVANCE Collaborative Group.
33. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
34. American Diabetes, Association Standards of medical care in diabetes-2011. Diabetes Care 2011, 34(Suppl 1):S11-S61.
35. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
36. Wilcox R., Bousser M.G., Betteridge D.J., Schernthaner G., Pirags V., Kupfer S., et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007, 38:865-873.
37. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008, 25:457-507. European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee.
38. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180-1188.
39. Furie K.L., Kasner S.E., Adams R.J., Albers G.W., Bush R.L., Fagan S.C., et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011, 42:227-276.
40. Zhang X., Patel A., Horibe H., Wu Z., Barzi F., Rodgers A., et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003, 32:563-572.
41. Horenstein R.B., Smith D.E., Mosca L. Cholesterol predicts stroke mortality in the Women's Pooling Project. Stroke 2002, 33:1863-1868.
42. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
43. Collins R., Armitage J., Parish S., Sleight P., Peto R. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004, 363:757-767.
44. Everett B.M., Glynn R.J., MacFadyen J.G., Ridker P.M. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein:justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation 2010, 121:143-150.
45. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
46. Amarenco P., Bogousslavsky J., Callahan A., Goldstein L.B., Hennerici M., Rudolph A.E., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006, 355:549-559.
47. Goldstein L.B., Amarenco P., Szarek M., Callahan A., Hennerici M., Sillesen H., et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008, 70(24 Pt 2):2364-2370.
48. Amarenco P., Goldstein L.B., Szarek M., Sillesen H., Rudolph A.E., Callahan A., et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007, 38:3198-3204.
49. Costa J., Borges M., David C., Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006, 332:1115-1124.
50. Paul S.L., Thrift A.G., Donnan G.A. Smoking as a crucial independent determinant of stroke. Tob Induc Dis 2004, 2:67-80.
51. Wolf P.A., D'Agostino R.B., Kannel W.B., Bonita R., Belanger A.J. Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA 1988, 259:1025-1029.
52. Haheim L.L., Holme I., Hjermann I., Leren P. Smoking habits and risk of fatal stroke: 18 years follow up of the Oslo Study. J Epidemiol Community Health 1996, 50:621-624.
53. Shinton R., Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989, 298:789-794.
54. Bonita R., Scragg R., Stewart A., Jackson R., Beaglehole R. Cigarette smoking and risk of premature stroke in men and women. Br Med J (Clin Res Ed) 1986, 293:6-8.
55. Kurth T., Kase C.S., Berger K., Schaeffner E.S., Buring J.E., Gaziano J.M. Smoking and the risk of hemorrhagic stroke in men. Stroke 2003, 34:1151-1155.
56. Bhat V.M., Cole J.W., Sorkin J.D., Wozniak M.A., Malarcher A.M., Giles W.H., et al. Dose-response relationship between cigarette smoking and risk of ischemic stroke in young women. Stroke 2008, 39:2439-2443.
57. Wannamethee S.G., Shaper A.G., Walker M. Changes in physical activity, mortality, and incidence of coronary heart disease in older men. Lancet 1998, 351:1603-1608.
58. Fagerstrom K. The epidemiology of smoking: health consequences and benefits of cessation. Drugs 2002, 62(Suppl 2):1-9.
59. Robbins A.S., Manson J.E., Lee I.M., Satterfield S., Hennekens C.H. Cigarette smoking and stroke in a cohort of U.S. male physicians. Ann Intern Med 1994, 120:458-462.
60. Critchley J.A., Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003, 290:86-97.
61. Bonita R., Duncan J., Truelsen T., Jackson R.T., Beaglehole R. Passive smoking as well as active smoking increases the risk of acute stroke. Tob Control 1999, 8:156-160.
62. You R.X., Thrift A.G., McNeil J.J., Davis S.M., Donnan G.A. Ischemic stroke risk and passive exposure to spouses' cigarette smoking. Melbourne Stroke Risk Factor Study (MERFS) Group. Am J Public Health 1999, 89:572-575.
63. García-Nunez C., Saez J., García-Nunez J.M., Grau J., Molto-Jorda J.M., Matias-Guiu J. Passive smoking as a cerebrovascular risk factor. Rev Neurol 2007, 45:577-581.
64. Boffetta P., Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. BMJ 2009, 339:b3060.
65. Gill J.S., Zezulka A.V., Shipley M.J., Gill S.K., Beevers D.G. Stroke and alcohol consumption. N Engl J Med 1986, 315:1041-1046.
66. Klatsky A.L., Armstrong M.A., Friedman G.D., Sidney S. Alcohol drinking and risk of hemorrhagic stroke. Neuroepidemiology 2002, 21:115-122.
67. Mazzaglia G., Britton A.R., Altmann D.R., Chenet L. Exploring the relationship between alcohol consumption and non-fatal or fatal stroke: a systematic review. Addiction 2001, 96:1743-1756.
68. Iso H., Baba S., Mannami T., Sasaki S., Okada K., Konishi M., et al. Alcohol consumption and risk of stroke among middle-aged men: the JPHC Study Cohort I. Stroke 2004, 35:1124-1129.
69. Reynolds K., Lewis B., Nolen J.D., Kinney G.L., Sathya B., He J. Alcohol consumption and risk of stroke: a meta-analysis. JAMA 2003, 289:579-588.
70. Berger K., Ajani U.A., Kase C.S., Gaziano J.M., Buring J.E., Glynn R.J., et al. Light-to-moderate alcohol consumption and risk of stroke among U.S. male physicians. N Engl J Med 1999, 341:1557-1564.
71. O'Keefe J.H., Bybee K.A., Lavie C.J. Alcohol and cardiovascular health: the razor-sharp double-edged sword. J Am Coll Cardiol 2007, 50:1009-1014.
72. Emberson J.R., Bennett D.A. Effect of alcohol on risk of coronary heart disease and stroke: causality, bias, or a bit of both?. Vasc Health Risk Manag 2006, 2:239-249.
73. Di Castelnuovo A., Rotondo S., Iacoviello L., Donati M.B., De Gaetano G. Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 2002, 105:2836-2844.
74. Sacks F.M., Svetkey L.P., Vollmer W.M., Appel L.J., Bray G.A., Harsha D., et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001, 344:3-10.
75. Appel L.J., Sacks F.M., Carey V.J., Obarzanek E., Swain J.F., Miller E.R., et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA 2005, 294:2455-2464.
76. Estruch R., Martínez-González M.A., Corella D., Salas-Salvado J., Ruiz-Gutiérrez V., Covas M.I., et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med 2006, 145:1-11.
77. Strazzullo P., D'Elia L., Kandala N.B., Cappuccio F.P. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ 2009, 339:b4567.
78. Mozaffarian D., Rimm E.B. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 2006, 296:1885-1899.
79. He K., Song Y., Daviglus M.L., Liu K., Van Horn L., Dyer A.R., et al. Fish consumption and incidence of stroke: a meta-analysis of cohort studies. Stroke 2004, 35:1538-1542.
80. Dauchet L., Amouyel P., Dallongeville J. Fruit and vegetable consumption and risk of stroke: a meta-analysis of cohort studies. Neurology 2005, 65:1193-1197.
81. Heidemann C., Schulze M.B., Franco O.H., van Dam R.M., Mantzoros C.S., Hu F.B. Dietary patterns and risk of mortality from cardiovascular disease, cancer, and all causes in a prospective cohort of women. Circulation 2008, 118:230-237.
82. Osler M., Heitmann B.L., Gerdes L.U., Jorgensen L.M., Schroll M. Dietary patterns and mortality in Danish men and women: a prospective observational study. Br J Nutr 2001, 85:219-225.
83. Bernstein M.S., Morabia A., Sloutskis D. Definition and prevalence of sedentarism in an urban population. Am J Public Health 1999, 89:862-867.
84. Wendel-Vos G.C., Schuit A.J., Feskens E.J., Boshuizen H.C., Verschuren W.M., Saris W.H., et al. Physical activity and stroke. A meta-analysis of observational data. Int J Epidemiol 2004, 33:787-798.
85. Mozaffarian D., Wilson P.W., Kannel W.B. Beyond established and novel risk factors: lifestyle risk factors for cardiovascular disease. Circulation 2008, 117:3031-3038.
86. Mora S., Cook N., Buring J.E., Ridker P.M., Lee I.M. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation 2007, 116:2110-2118.
87. Thompson P.D., Buchner D., Pina I.L., Balady G.J., Williams M.A., Marcus B.H., et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003, 107:3109-3116.
88. Netz Y., Wu M.J., Becker B.J., Tenenbaum G. Physical activity and psychological well-being in advanced age: a meta-analysis of intervention studies. Psychol Aging 2005, 20:272-284.
89. Bassuk S.S., Manson J.E. Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol 2005, 99:1193-1204.
90. Taylor A.H., Ussher M.H., Faulkner G. The acute effects of exercise on cigarette cravings, withdrawal symptoms, affect and smoking behaviour: a systematic review. Addiction 2007, 102:534-543.
91. Lee C.D., Folsom A.R., Blair S.N. Physical activity and stroke risk: a meta-analysis. Stroke 2003, 34:2475-2481.
92. Shiroma E.J., Lee I.M. Physical activity and cardiovascular health: lessons learned from epidemiological studies across age, gender, and race/ethnicity. Circulation 2010, 122:743-752.
93. Physical activity and cardiovascular health. JAMA 1996, 276:241-246. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health.
94. De Weerd M., Greving J.P., Hedblad B., Lorenz M.W., Mathiesen E.B., O'Leary D.H., et al. Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis. Stroke 2010, 41:1294-1297.
95. Nadareishvili Z.G., Rothwell P.M., Beletsky V., Pagniello A., Norris J.W. Long-term risk of stroke and other vascular events in patients with asymptomatic carotid artery stenosis. Arch Neurol 2002, 59:1162-1166.
96. Halliday A., Mansfield A., Marro J., Peto C., Peto R., Potter J., et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004, 363:1491-1502.
97. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995, 273:1421-1428. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
98. Marquardt L., Geraghty O.C., Mehta Z., Rothwell P.M. Low risk of ipsilateral stroke in patients with asymptomatic carotid stenosis on best medical treatment: a prospective, population-based study. Stroke 2010, 41:e11-e17.
99. Abbott A.L. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke 2009, 40:e573-e583.
100. Spence J.D., Coates V., Li H., Tamayo A., Munoz C., Hackam D.G., et al. Effects of intensive medical therapy on microemboli and cardiovascular risk in asymptomatic carotid stenosis. Arch Neurol 2010, 67:180-186.
101. Brott T.G., Hobson R.W., Howard G., Roubin G.S., Clark W.M., Brooks W., et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010, 363:11-23.
102. Brott T.G., Halperin J.L., Abbara S., Bacharach J.M., Barr J.D., Bush R.L., et al. TASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Stroke 2011, 42:e420-e463.
103. Liapis C.D., Bell P.R., Mikhailidis D., Sivenius J., Nicolaides A., Fernandes e Fernandes J., et al. ESVS guidelines. Invasive treatment for carotid stenosis: indications, techniques. Eur J Vasc Endovasc Surg 2009, 37(4 Suppl):1-19.
104. Nicolaides A.N., Kakkos S., Griffin M., Geroulakos G., Ioannidou E. Severity of asymptomatic carotid stenosis and risk of ipsilateral hemispheric ischaemic events: results from the ACSRS study. Nicolaides et al.: EJVES 2005; 30: 275-284. Eur J Vasc Endovasc Surg 2006, 31:336.
105. Kakkos S.K., Sabetai M., Tegos T., Stevens J., Thomas D., Griffin M., et al. Silent embolic infarcts on computed tomography brain scans and risk of ipsilateral hemispheric events in patients with asymptomatic internal carotid artery stenosis. J Vasc Surg 2009, 49:902-909.
106. Sabeti S., Schlager O., Exner M., Mlekusch W., Amighi J., Dick P., et al. Progression of carotid stenosis detected by duplex ultrasonography predicts adverse outcomes in cardiovascular high-risk patients. Stroke 2007, 38:2887-2894.
107. Markus H.S., King A., Shipley M., Topakian R., Cullinane M., Reihill S., et al. Asymptomatic embolisation for prediction of stroke in the Asymptomatic Carotid Emboli Study (ACES): a prospective observational study. Lancet Neurol 2010, 9:663-671.
108. van Wijk I., Koudstaal P.J., Kappelle L.J., van Gijn J., Gorter J.W., Algra A., et al. Long-term occurrence of death and cardiovascular events in patients with transient ischaemic attack or minor ischaemic stroke: comparison between arterial and cardiac source of the index event. J Neurol Neurosurg Psychiatry 2008, 79:895-899.
109. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375.
110. Lakshminarayan K., Solid C.A., Collins A.J., Anderson D.C., Herzog C.A. Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002). Stroke 2006, 37:1969-1974.
111. Hart R.G., Halperin J.L. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999, 131:688-695.
112. Sacco R.L., Benjamin E.J., Broderick J.P., Dyken M., Easton J.D., Feinberg W.M., et al. American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke Risk factors. Stroke 1997, 28:1507-1517.
113. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983-988.
114. Wolf P.A., Dawber T.R., Thomas H.E., Kannel W.B. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978, 28:973-977.
115. Hart R.G., Pearce L.A. Current status of stroke risk stratification in patients with atrial fibrillation. Stroke 2009, 40:2607-2610.
116. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
117. Rietbrock S., Heeley E., Plumb J., van Staa T. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure. Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J 2008, 156:57-64.
118. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010, 137:263-272.
119. Bonow R.O., Carabello B.A., Chatterjee K., De León A.C., Faxon D.P., Freed M.D., et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008, 52:e1-e142.
120. Olesen K.H. The natural history of 271 patients with mitral stenosis under medical treatment. Br Heart J 1962, 24:349-357.
121. Liu T.J., Lai H.C., Lee W.L., Wang K.Y., Wei H.J., Ting C.T., et al. Percutaneous balloon commissurotomy reduces incidence of ischemic cerebral stroke in patients with symptomatic rheumatic mitral stenosis. Int J Cardiol 2008, 123:189-190.
122. Karas M.G., Francescone S., Segal A.Z., Devereux R.B., Roman M.J., Liu J.E., et al. Relation between mitral annular calcium and complex aortic atheroma in patients with cerebral ischemia referred for transesophageal echocardiography. Am J Cardiol 2007, 99:1306-1311.
123. Pujadas R., Arboix A., Anguera N., Rafel J., Sagues F., Casanas R. Mitral annular calcification as a marker of complex aortic atheroma in patients with stroke of uncertain etiology. Echocardiography 2008, 25:124-132.
124. Kohsaka S., Jin Z., Rundek T., Boden-Albala B., Homma S., Sacco R.L., et al. Impact of mitral annular calcification on cardiovascular events in a multiethnic community: the Northern Manhattan Study. JACC Cardiovasc Imaging 2008, 1:617-623.
125. Kizer J.R., Wiebers D.O., Whisnant J.P., Galloway J.M., Welty T.K., Lee E.T., et al. Mitral annular calcification, aortic valve sclerosis, and incident stroke in adults free of clinical cardiovascular disease: the Strong Heart Study. Stroke 2005, 36:2533-2537.
126. Freed L.A., Levy D., Levine R.A., Larson M.G., Evans J.C., Fuller D.L., et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999, 341:1-7.
127. Weir N.U. An update on cardioembolic stroke. Postgrad Med J 2008, 84:133-142. quiz 139-40.
128. Hirsh J., Guyatt G., Albers G.W., Harrington R., Schunemann H.J. American College of Chest Physicians. Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6 Suppl):71S-109S.
129. Antman E.M., Hand M., Armstrong P.W., Bates E.R., Green L.A., Halasyamani L.K., et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Writing on Behalf of the 2004 Writing Committee. Circulation 2008, 117:296-329.
130. Becker R.C., Meade T.W., Berger P.B., Ezekowitz M., O'Connor C.M., Vorchheimer D.A., et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6 Suppl):776S-814S.
131. Di Tullio M.R., Sacco R.L., Sciacca R.R., Jin Z., Homma S. Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J Am Coll Cardiol 2007, 49:797-802.
132. Meissner I., Khandheria B.K., Heit J.A., Petty G.W., Sheps S.G., Schwartz G.L., et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol 2006, 47:440-445.
133. Overell J.R., Bone I., Lees K.R. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000, 55:1172-1179.
134. Mas J.L., Arquizan C., Lamy C., Zuber M., Cabanes L., Derumeaux G., et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001, 345:1740-1746.
135. Serena J., Marti-Fabregas J., Santamarina E., Rodríguez J.J., Pérez-Ayuso M.J., Masjuan J., et al. Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study. Stroke 2008, 39:3131-3136.
136. Almekhlafi M.A., Wilton S.B., Rabi D.M., Ghali W.A., Lorenzetti DL Hill MD. Recurrent cerebral ischemia in medically treated patent foramen ovale: a meta-analysis. Neurology 2009, 73:89-97.
137. Grodstein F., Stampfer M.J., Manson J.E., Colditz G.A., Willett W.C., Rosner B., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996, 335:453-461.
138. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
139. Wassertheil-Smoller S., Hendrix S.L., Limacher M., Heiss G., Kooperberg C., Baird A., et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003, 289:2673-2684.
140. Rossouw J.E., Prentice R.L., Manson J.E., Wu L., Barad D., Barnabei V.M., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007, 297:1465-1477.
141. Gabriel S.R., Carmona L., Roque M., Sanchez G.L., Bonfill X. Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2005, 2:CD002229.
142. Sare G.M., Gray L.J., Bath P.M. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008, 29:2031-2041.
143. Renoux C., Dell'aniello S., Garbe E., Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010, 340:c2519.
144. De Melo N.R., Pompei L.M. Tibolone reduces osteoporotic fracture risk and breast cancer risk, but increases the risk of stroke. Gynecol Endocrinol 2010, 26:73-75.
145. Nelson H.D., Fu R., Griffin J.C., Nygren P., Smith M.E., Humphrey L. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med 2009, 151:703-715.
146. Barrett-Connor E., Cox D.A., Song J., Mitlak B., Mosca L., Grady D. Raloxifene and risk for stroke based on the framingham stroke risk score. Am J Med 2009, 122:754-761.
147. Viscoli C.M., Brass L.M., Kernan W.N., Sarrel P.M., Suissa S., Horwitz R.I. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001, 345:1243-1249.
148. Brass L.M. Hormone replacement therapy and stroke: clinical trials review. Stroke 2004, 35(11 Suppl 1):2644-2647.
149. Bath P.M., Gray L.J. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005, 330:342.
150. Chan W.S., Ray J., Wai E.K., Ginsburg S., Hannah M.E., Corey P.N., et al. Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch Intern Med 2004, 164:741-747.
151. Baillargeon J.P., McClish D.K., Essah P.A., Nestler J.E. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005, 90:3863-3870.
152. Chakhtoura Z., Canonico M., Gompel A., Thalabard J.C., Scarabin P.Y., Plu-Bureau G. Progestogen-only contraceptives and the risk of stroke: a meta-analysis. Stroke 2009, 40:1059-1062.
153. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996, 348:498-505.
154. Schwartz S.M., Siscovick D.S., Longstreth W.T., Psaty B.M., Beverly R.K., Raghunathan T.E., et al. Use of low-dose oral contraceptives and stroke in young women. Ann Intern Med 1997, 127(8 Pt 1):596-603.
155. Becker W.J. Use of oral contraceptives in patients with migraine. Neurology 1999, 53(4 Suppl 1):S19-S25.
156. Siritho S., Thrift A.G., McNeil J.J., You R.X., Davis S.M., Donnan G.A., et al. Risk of ischemic stroke among users of the oral contraceptive pill: The Melbourne Risk Factor Study (MERFS) Group. Stroke 2003, 34:1575-1580.
157. Lidegaard O., Oral contraceptives pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol 1995, 102:153-159.
158. Dentali F., Crowther M., Ageno W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood 2006, 107:2766-2773.
159. Martinelli I., Battaglioli T., Burgo I., Di Domenico S., Mannucci P.M. Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. Haematologica 2006, 91:844-847.
160. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288:2015-2022. Homocysteine Studies Collaboration.
161. Casas J.P., Bautista L.E., Smeeth L., Sharma P., Hingorani A.D. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005, 365:224-232.
162. Wald D.S., Law M., Morris J.K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325:1202.
163. Toole J.F., Malinow M.R., Chambless L.E., Spence J.D., Pettigrew L.C., Howard V.J., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004, 291:565-575.
164. Lonn E., Yusuf S., Arnold M.J., Sheridan P., Pogue J., Micks M., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006, 354:1567-1577.
165. Bonaa K.H., Njolstad I., Ueland P.M., Schirmer H., Tverdal A., Steigen T., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006, 354:1578-1588.
166. Wang X., Qin X., Demirtas H., Li J., Mao G., Huo Y., et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007, 369:1876-1882.
167. Bazzano L.A., Reynolds K., Holder K.N., He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006, 296:2720-2726.
168. VITATOPS Trial Study Group B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 2010, 9:855-865.
169. Spence J.D. Homocysteine-lowering therapy: a role in stroke prevention?. Lancet Neurol 2007, 6:830-838.
170. Marti-Carvajal A.J., Sola I., Lathyris D., Salanti G. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2009, 4:CD006612.
171. Ridker P.M., Hennekens C.H., Lindpaintner K., Stampfer M.J., Eisenberg P.R., Miletich J.P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995, 332:912-917.
172. Cushman M., Rosendaal F.R., Psaty B.M., Cook E.F., Valliere J., Kuller L.H., Factor V, et al. Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost 1998, 79:912-915.
173. Feinberg W.M., Pearce L.A., Hart R.G., Cushman M., Cornell E.S., Lip G.Y., et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 1999, 30:2547-2553.
174. Juul K., Tybjaerg-Hansen A., Steffensen R., Kofoed S., Jensen G., Nordestgaard B.G. Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood 2002, 100:3-10.
175. Ridker P.M., Hennekens C.H., Miletich J.P. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999, 99:999-1004.
176. Rahemtullah A., Van Cott E.M. Hypercoagulation testing in ischemic stroke. Arch Pathol Lab Med 2007, 131:890-901.
177. Martínez-Martínez M., Cazorla-Garcia R., Rodríguez de Antonio L.A., Martínez-Sánchez P., Fuentes B., Díez-Tejedor E. Hypercoagulability and ischemic stroke in young patients. Neurologia 2010, 25:343-348.
178. Kenet G., Lutkhoff L.K., Albisetti M., Bernard T., Bonduel M., Brandao L., et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation 2010, 121:1838-1847.
179. Casas J.P., Hingorani A.D., Bautista L.E., Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol 2004, 61:1652-1661.
180. Kim R.J., Becker R.C. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003, 146:948-957.
181. Cohn D., Vansenne F., De Borgie C., Middeldorp S. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev 2009, 1:CD007069.
182. Finazzi G., Brancaccio V., Moia M., Ciaverella N., Mazzucconi M.G., Schinco P.C., et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996, 100:530-536.
183. Brey R.L., Abbott R.D., Curb J.D., Sharp D.S., Ross G.W., Stallworth C.L., et al. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program. Stroke 2001, 32:1701-1706.
184. Janardhan V., Wolf P.A., Kase C.S., Massaro J.M., D'Agostino R.B., Franzblau C., et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke 2004, 35:736-741.
185. Lim W., Crowther M.A., Eikelboom J.W. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006, 295:1050-1057.
186. Brey R.L. Management of the neurological manifestations of APS--what do the trials tell us?. Thromb Res 2004, 114:489-499.
187. Gatenby P.A. Controversies in the antiphospholipid syndrome and stroke. Thromb Res 2004, 114:483-488.
188. Young T., Palta M., Dempsey J., Skatrud J., Weber S., Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993, 328:1230-1235.
189. Marín J.M., Carrizo S.J., Vicente E., Agusti A.G. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005, 365:1046-1053.
190. Javaheri S., Parker T.J., Liming J.D., Corbett W.S., Nishiyama H., Wexler L., et al. Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations. Circulation 1998, 97:2154-2159.
191. Goldberger J.J., Cain M.E., Hohnloser S.H., Kadish A.H., Knight B.P., Lauer M.S., et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation 2008, 118:1497-1518.
192. Gottlieb D.J., Yenokyan G., Newman A.B., O'Connor G.T., Punjabi N.M., Quan S.F., et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation 2010, 122:352-360.
193. Redline S., Yenokyan G., Gottlieb D.J., Shahar E., O'Connor G.T., Resnick H.E., et al. Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. Am J Respir Crit Care Med 2010, 182:269-277.
194. Yaggi H.K., Concato J., Kernan W.N., Lichtman J.H., Brass L.M., Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005, 353:2034-2041.
195. Arzt M., Young T., Finn L., Skatrud J.B., Bradley T.D. Association of sleep-disordered breathing and the occurrence of stroke. Am J Respir Crit Care Med 2005, 172:1447-1451.